Cidara Therapeutics Inc (NASDAQ:CDTX) – Research analysts at Leerink Swann upped their Q1 2018 EPS estimates for shares of Cidara Therapeutics in a report released on Wednesday, according to Zacks Investment Research. Leerink Swann analyst P. Matteis now forecasts that the biotechnology company will post earnings per share of ($0.63) for the quarter, up from their previous estimate of ($0.66). Leerink Swann also issued estimates for Cidara Therapeutics’ Q2 2018 earnings at ($0.46) EPS, Q3 2018 earnings at ($0.66) EPS, Q4 2018 earnings at ($0.80) EPS, FY2018 earnings at ($2.55) EPS and FY2019 earnings at ($2.82) EPS.
Cidara Therapeutics (NASDAQ:CDTX) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.05.
A number of other analysts also recently commented on the company. Cantor Fitzgerald set a $15.00 price objective on Cidara Therapeutics and gave the stock a “buy” rating in a report on Thursday, March 8th. Zacks Investment Research downgraded Cidara Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 12th. One analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $13.56.
Cidara Therapeutics (NASDAQ:CDTX) traded up $0.10 during mid-day trading on Monday, hitting $8.15. The stock had a trading volume of 112,537 shares, compared to its average volume of 114,855. The firm has a market cap of $162.92 and a P/E ratio of -2.54. The company has a current ratio of 6.43, a quick ratio of 6.43 and a debt-to-equity ratio of 0.12. Cidara Therapeutics has a 1-year low of $5.60 and a 1-year high of $8.80.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its position in Cidara Therapeutics by 26.2% in the 4th quarter. Renaissance Technologies LLC now owns 179,300 shares of the biotechnology company’s stock valued at $1,219,000 after buying an additional 37,197 shares during the last quarter. Prosight Management LP bought a new position in shares of Cidara Therapeutics during the fourth quarter worth about $11,206,000. Broadfin Capital LLC lifted its position in shares of Cidara Therapeutics by 4.5% during the fourth quarter. Broadfin Capital LLC now owns 857,397 shares of the biotechnology company’s stock worth $5,830,000 after purchasing an additional 36,994 shares during the last quarter. Eversept Partners LLC bought a new position in shares of Cidara Therapeutics during the fourth quarter worth about $340,000. Finally, OxFORD Asset Management LLP lifted its position in shares of Cidara Therapeutics by 69.1% during the third quarter. OxFORD Asset Management LLP now owns 22,181 shares of the biotechnology company’s stock worth $187,000 after purchasing an additional 9,065 shares during the last quarter. Hedge funds and other institutional investors own 66.95% of the company’s stock.
About Cidara Therapeutics
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.